4.5 Article

Characteristics of Children With Elevated Symptoms of Mania: The Longitudinal Assessment of Manic Symptoms (LAMS) Study

Journal

JOURNAL OF CLINICAL PSYCHIATRY
Volume 71, Issue 12, Pages 1664-1672

Publisher

PHYSICIANS POSTGRADUATE PRESS
DOI: 10.4088/JCP.09m05859yel

Keywords

-

Funding

  1. Abbott
  2. Addrenex
  3. AstraZeneca
  4. Biovail
  5. Bristol-Myers Squibb
  6. Forest
  7. GlaxoSmithKline
  8. Johnson Johnson
  9. KemPharm
  10. Eli Lilly
  11. Lundbeck
  12. Neuropharm
  13. Novartis
  14. Organon
  15. Otsuka
  16. Pfizer
  17. Sanofi-Aventis
  18. Sepracor
  19. Shire
  20. Solvay
  21. Supernus
  22. Validus
  23. Wyeth
  24. National Alliance for Research on Schizophrenia and Depression
  25. National Institute of Child Health and Human Development
  26. Stanley Foundation
  27. Celgene
  28. Sigma Tau
  29. Targacept
  30. National Institute of Mental Health (NIMH)

Ask authors/readers for more resources

Objective: The aim of the Longitudinal Assessment of Manic Symptoms (LAMS) study is to examine differences in psychiatric symptomatology, diagnoses, demographics, functioning, and psychotropic medication exposure in children with elevated symptoms of mania (ESM) compared to youth without ESM. This article describes the initial demographic information, diagnostic and symptom prevalence, and medication exposure for the LAMS cohort that will be followed longitudinally. Method: Guardians of consecutively ascertained new outpatients 6 to 12 years of age presenting for treatment at one of 10 university-affiliated mental health centers were asked to complete the Parent General Behavior Inventory-10-Item Mania Scale (PGBI-10M). Patients with scores 12 on the PGBI-10M (ESM+) and a matched sample of patients who screened negative (ESM-) were invited to participate. Patients were enrolled from December 13, 2005, to December 18, 2008. Results: 707 children (621 ESM+, 86 ESM-; mean [SD] age = 9.4 [2.0] years) were evaluated. The ESM+ group, compared to the ESM- group, more frequently met DSM-IV criteria for a mood disorder (P<.001), bipolar spectrum disorders (BPSD; P<.001), and disruptive behavior disorders (P<.01). Furthermore, they showed poorer overall functioning and more severe manic, depressive, attention-deficit/hyperactivity, disruptive behavioral, and anxiety symptoms. Nevertheless, rates of BPSD were relatively low in the ESM+ group (25%), with almost half of these BPSD patients (12.1% of ESM+ patients) meeting DSM-IV criteria for bipolar disorder not otherwise specified. ESM+ children with BPSD had significantly more of the following: current prescriptions for antipsychotics, mood stabilizers, and anticonvulsants (P<.001 for each); psychiatric hospitalizations (P<.001); and biological parents with elevated mood (P=.001 for mothers, P<.013 for fathers). ESM+ children with BPSD were also lower functioning compared to ESM+ children without BPSD. Conclusions: Although ESM+ was associated with higher rates of BPSD than ESM-, 75% of ESM+ children did not meet criteria for BPSD. Results suggest that longitudinal assessment is needed to examine which factors are associated with diagnostic evolution to BPSD in children with elevated symptoms of mania. J Clin Psychiatry 2010;71(12):1664-1672 (C) Copyright 2010 Physicians Postgraduate Press, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available